• Key Findings of the NIAGARA and HIMALAYA Trials

  • Nov 8 2024
  • Length: 13 mins
  • Podcast

Key Findings of the NIAGARA and HIMALAYA Trials

Listen for free

View show details

  • Summary

  • In this episode of the Pharmaceutical Executive podcast, Shubh Goel, Head of Immuno-Oncology and Gastrointestinal Tumors, US Oncology Business Unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer, and much more.
    Show more Show less
Show more Show less
activate_Holiday_promo_in_buybox_DT_T2

What listeners say about Key Findings of the NIAGARA and HIMALAYA Trials

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews
No Reviews are Available